PCSK9 inhibitor
Enlicitide’s Phase 3 Triumphs Herald New Era for PCSK9 Inhibitors and Cholesterol Management
Merck’s enlicitide achieves Phase 3 endpoints, signaling a shift toward oral PCSK9 therapy that complements global injectables like Repatha and Praluent, siRNA therapy Leqvio, and emerging domestic inhibitors such as Sintbilo.